Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Biofrontera (BFRI) over the last 6 years, with Q3 2025 value amounting to $285000.0.

  • Biofrontera's Gains from Investment Securities fell 5808.82% to $285000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$767000.0, marking a year-over-year increase of 8518.73%. This contributed to the annual value of $1.4 million for FY2024, which is 126573.79% up from last year.
  • Biofrontera's Gains from Investment Securities amounted to $285000.0 in Q3 2025, which was down 5808.82% from -$153000.0 recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Gains from Investment Securities ranged from a high of $1.8 billion in Q3 2022 and a low of -$5.4 million during Q2 2022
  • Moreover, its 5-year median value for Gains from Investment Securities was $2000.0 (2021), whereas its average is $128.7 million.
  • The largest annual percentage gain for Biofrontera's Gains from Investment Securities in the last 5 years was 6038950000.0% (2022), contrasted with its biggest fall of 26865000.0% (2022).
  • Biofrontera's Gains from Investment Securities (Quarter) stood at $12.8 million in 2021, then tumbled by 108.76% to -$1.1 million in 2022, then crashed by 297.41% to -$4.5 million in 2023, then skyrocketed by 92.12% to -$351000.0 in 2024, then surged by 181.2% to $285000.0 in 2025.
  • Its Gains from Investment Securities was $285000.0 in Q3 2025, compared to -$153000.0 in Q2 2025 and -$548000.0 in Q1 2025.